Melissa Carpenter PhD


Dr. Carpenter is Principal of the Carpenter Group Consulting Inc. She received a Ph.D. in the Laboratory of Cellular and Molecular Neurobiology, University of California, Irvine. For the last 15 years, she has worked on the development of cell therapies using human adult and embryonic stem cells, in academia and industry. Her work involved discovery and translation including developing strategies for preclinical development and navigating the regulatory process.

At CytoTherapeutics (now StemCells, Inc), Dr. Carpenter derived human neural stem cells and developed the media formulation for scale-up. She has been involved with human embryonic stem cell research from the beginning. As Director of Stem Cell Biology, Geron Corporation she was responsible for managing discovery research and preclinical programs for Parkinson's disease, spinal cord injury, cardiac disease, liver disease and diabetes. After leaving Geron, Dr. Carpenter was Principal Investigator and Scientist at the Robarts Research Institute and Associate Professor, Faculty of Medicine, University of Western Ontario focusing on the epigenetic status of undifferentiated human embryonic stem cells and the signaling mechanisms involved in self-renewal. As Vice President of R&D at Novocell Inc, Dr. Carpenter was responsible for the translation and regulatory strategy for the delivery of an encapsulated human embryonic stem cell derived product for diabetics.

Dr. Carpenter has 20+ issued patents and 45+ publications in stem cell biology and related fields.

Daniel Kraft, M.D.

Daniel Kraft , M.D.

Dr. Kraft is a Stanford and Harvard trained physician scientist and innovator in the field of stem cells and regenerative medicine with over 20 years of clinical and biomedical research experience. He is an NIH funded faculty member with the Stanford Institute for Stem Cell Biology and Regenerative Medicine and is on clinical faculty with the UCSF pediatric bone marrow transplantation service.

Dr. Kraft has extensive research experience focused on stem cell biology and immunology. In early research experience at the National Institutes of Health, he was the first to propose and demonstrate proof of concept for a monoclonal antibody based therapy for allergic disease, an approach later translated to a novel humanized antibody therapeutic by Genentech (Xolair). Research at Brown University, and later at Harvard medical school focused on HIV and its interaction with the immune system. As a Howard Hughes research fellow at Stanford he discovered a novel population of developing human T-cells. Dr. Kraft also was a research fellow with SyStemix, a company which pioneered purified hematopoietic stem cells.

Carol Walton, PhD

Carol Walton, PhD

Carol has a unique knowledge of the development and commercialisation of cell therapy. Her expertise includes understanding the influences of key stakeholders (including: regulators, clinicians and healthcare insurers) on the development of cell-based therapies. Carol is widely networked and has conducted numerous cell therapy development case studies with key opinion leaders from industry, FDA, EMA and the Centers for Medicare & Medicaid Services. She has published a number of scientific papers and reports as well as a book chapter related to the commercialisation of cell-based therapies. She has also been highly instrumental in establishing The Regenerative Medicine Coalition. Carol was born and raised in Andorra. She graduated with a Bachelor’s and a Master’s degree in Bioengineering specialising in Biotechnology from the University of Brussels in 2008. She completed her Master’s thesis at the University of Oxford in Molecular Biology. Carol has also studied at the Universitat Autònoma de Barcelona in Spanish and Catalan for her Bioengineering degree in 2006-2007. Subsequently, in 2008-2009, Carol completed an M.Phil in Bioscience Enterprise at the University of Cambridge in affiliation with the Massachusetts Institute of Technology. Currently, she is a final year Doctoral Researcher working on the development and commercialisation of cell therapy at the University of Cambridge under the supervision of Dr. Paul Heffernan from the Institute for Manufacturing and Prof. Chris Lowe, Director of the Institute of Biotechnology.